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Major depression in outpatients attending a regional cancer
centre: screening and unmet treatment needs
M Sharpe*,1, V Strong1, K Allen2, R Rush3, K Postma2, A Tulloh2, P Maguire4, A House5, A Ramirez6 and A Cull2
1Division of Psychiatry, School of Molecular and Clinical Medicine, Kennedy Tower, Royal Edinburgh Hospital, Morningside Park, Edinburgh EH10 5HF,
UK; 2Cancer Research UK Psychological Medicine Research Group, Cancer Research Centre, Western General Hospital, Crewe Road, Edinburgh. EH4
2XR, UK; 3Cancer Research UK, Edinburgh Oncology Unit, Western General Hospital, Crewe Road, Edinburgh EH4 2XR, UK; 4Cancer Research
Campaign Psychological Medicine Group, Christie Hospital NHS Trust, Stanley House, Wilmslow Road, Withington, Manchester M20 4BX, UK; 5School of
Medicine, University of Leeds, 15 Hyde Terrace, Leeds LS2 9LT, UK; 6Department of Liaison Psychiatry and Cancer Research UK London Psychosocial
Group, Adamson Centre for Mental Health, South Wing, St Thomas’ Hospital, London SE1 7EH, UK
A screening programme designed to identify cases of Major Depressive Disorder (MDD) in patients attending a Regional Cancer
Centre outpatient department was established. It comprised two stages: (1) The Hospital Anxiety and Depression Scale (HADS) self-
rating questionnaire administered by a touch-screen computer; (2) we interviewed patients with high scores on the HADS (15 or
more total score) over the telephone using the depression section of the Structured Clinical Interview for DSMIV (SCID). A large
consecutive sample (5613) of oncology clinic attenders was screened, and practical difficulties in the screening process were
identified. The estimated prevalence of major depressive disorder (MDD) in the sample surveyed was approximately 8% (7.8%; 95%
confidence intervals 6.9–8.5%). We assessed a consecutive series of 150 patients identified as having MDD to determine how many
had received evidence-based treatment for MDD. Only half had discussed their low mood with their general practitioner, only one-
third had been prescribed any antidepressant medication, and very few had taken a therapeutic dose for an adequate period. Very
few had received psychological treatment or had been referred to mental health services. Most were receiving no potentially effective
therapy.
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Depression is an important and neglected problem in medical
patients in general (Katon, 1996) and in cancer patients in
particular (Chochinov, 2001). Previous studies have estimated the
prevalence of Major Depressive Disorder (MDD) (American
Psychiatric Association, 1994) in cancer patients to be as high as
50% (McDaniel et al, 1995). Major depressive disorder has a
substantial impact on the quality of life of cancer patients and
leads to reduced compliance with medical treatment and poorer
outcome from it (McDaniel et al, 1995). Yet, studies show that
psychiatric disorder goes unrecognised and untreated (McDonald
et al, 1999; Fallowfield et al, 2001).
It has recently been recommended that all medical patients be
screened for depression (Pignone et al, 2002). Screening can
effectively detect cases of depression among oncology outpatients
(Cull et al, 2001), many of whom would otherwise have been
missed (Fallowfield et al, 2001). There is, however, little
information on the performance of such screening systems ‘in
the real world.’ How many cases of depression do such systems
actually deliver and in how many of these is there evidence of an
unmet need for treatment?
The study reported below is a description and evaluation of a
two-stage screening programme for MDD implemented in a large
cancer outpatient service in Edinburgh. The cases identified were
subsequently entered into a trial of depression management, which
is reported in a companion paper (Sharpe et al, 2003).
The aims of this study were: (1) to determine how many cases of
MDD a clinically feasible two-stage screening process identifies
among outpatients attending a large oncology outpatient service.
(2) To identify the extent of unmet need for treatment of those
patients identified as having MDD, who were potentially suitable
for treatment in a cancer centre-based depression service.
MATERIALS AND METHOD
Sample
The study sample was a consecutive series of 5613 outpatients aged
18 years or over, with a diagnosis of cancer who attended selected
outpatient clinics of a regional cancer service between September
1999 and September 2000. We chose clinics to screen with the aim
of obtaining a sample with representation of both sexes, a wide
range of ages and variety of cancer types. However, because we
were interested in identifying those patients who would live
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sufficiently long to benefit from treatment given over several
months, those clinics (such as those for lung cancer) in which
many of the patients had a very short life expectancy were
excluded. The clinics screened were for breast, gynae-oncology,
bladder, prostate, testicular, colorectal, and mixed cancer types.
Description of attenders In order to characterise the sample
screened, the age, sex, and cancer diagnosis of 792 (14%)
consecutive patients who attended the target clinics during 1
month in the middle of the sampling period (mid-June –mid-July
2000) had detailed clinical information abstracted from case notes.
Identification of cases of major depression
In order to minimise the number of diagnostic interviews
performed, patients with MDD were identified using a two-stage
procedure. The first stage was intended to define a group likely to
have MDD based on a self-rated questionnaire. Those scoring
above the chosen threshold on this questionnaire and eligible to
participate were then interviewed. Since it was difficult to arrange
this interview during their clinic visit, it was conducted at home
over the telephone.
Stage one The Hospital Anxiety and Depression Scale (HADS) , a
14-item self-administered rating scale, was specifically developed
to identify anxiety and depression in nonpsychiatric medical
outpatients (Zigmond and Snaith, 1983). It excludes somatic
symptoms of anxiety and depression. Two comprehensive reviews
have found it to be a reliable and valid screening instrument
(Herrman, 1997; Bjelland et al, 2002); it is quick and easy to
administer and well accepted by patients. We used a total score
cutoff of 15 because this was previously reported to offer good
sensitivity and specificity (Ibbotson et al, 1994). We also examined
the performance of the HAD by interviewing a consecutive series
of 361 patients. This study (reported fully elsewhere) found that
this cutoff performed adequately (sensitivity 87% and specificity
85%) and missed few interview positive cases. We administered
the HADS by either a touch-screen computer (Cull et al, 2001) or
when a computer was unavailable, by pen and paper. Good
reliability between these two methods of administration has been
previously reported (Velikova et al, 1999). We therefore con-
sidered the combined data collected by both these methods.
Stage two
The section for diagnosing MDD from the Structured Clinical
Interview for DSM-IV Axis I Disorders (SCID) (Spitzer et al, 1992)
was administered over the telephone. This structured psychiatric
interview ascertains the presence of the symptoms of MDD. If five
or more symptoms from a list of symptoms, at least one of which
must be depressed mood or anhedonia, have been present for 2 or
more weeks, the diagnosis of MDD is made. In making the
diagnosis of depression, all identified symptoms were counted
without making a judgement about whether they should be
attributed to cancer or to depression. This ‘inclusive approach’ is
the most widely used and was chosen to maximise the sensitivity
and inter-rater reliability of diagnoses (Koenig et al, 1997). All
interviews were audio recorded for final blind ratings.
Procedure
On arrival at the reception, patients were given an information
sheet about the screening procedure and invited to complete the
HADS questionnaire prior to their consultation. A research
assistant was present in the clinic to offer help if required.
Computer-generated HADS scores were produced from the touch-
screen questionnaires and the paper form of HADS was scored by
hand. These summaries were made available to the oncologist to
review during the consultation. Every time the patient visited the
oncology clinic during the trial period, screening was offered and
records were kept in the patient notes of the HAD scores on each
occasion.
Every patient with a HADS total score of 15 or over
was contacted by telephone within 2 weeks of their clinic
visit for the SCID interview (Ethical Committee approval for the
study was contingent upon the oncologist giving permission for
the patients to be contacted for interview). Three researchers who
had undergone training in SCID interviewing conducted the
interviews. The telephone-administered SCID has been previously
shown to have good agreement with a face-to-face interview
(Cacciola et al, 1999). Final ratings of MDD were made by
consensus between the interviewer and a consultant psychiatrist
(MS), who reviewed audio tape recordings of the interviews when
necessary.
In all cases diagnosed as having MDD, the patient’s general
practitioner was notified of the diagnosis by letter. Eligible patients
were asked for their consent to participate in a further research
assessment.
Patient characteristics and treatment needs
Our aim was to identify all those patients with MDD who could
feasibly be managed outside specialist mental health services by
oncology nurses and general practitioners. We therefore excluded
from further assessment patients with the following characteristics:
severe comorbid psychiatric illness (such as psychosis or bipolar
disorder); severe cognitive impairment; chronic depression (i.e.
depression present for a year or more prior to cancer diagnosis);
depression associated with significant alcohol or substance abuse;
and patients with complicating medical problems that required
active management (such as cerebral metastases/poorly controlled
epilepsy). As we were focusing on the needs of those with
reasonable life expectancy, we also excluded those expected to die
within 6 months.
Patients who met both diagnostic criteria for MDD and the
above eligibility requirements were asked additional questions
during the telephone interview. These aimed to ascertain: (a) when
the current episode of depression started; (b) the number and
duration of previous episodes; (c) what treatment, if any, the
patient had received and was currently receiving; (d) current and
previous use of mental health services; (e) current antidepressant
drugs prescribed and the adequacy of dosage; and (f) adherence to
the prescribed antidepressant drugs.
Definition of adequate treatment There is uncertainty about what
is the best treatment for MDD in patients with cancer. We have
assumed that conventional evidence-based treatments for depres-
sion in the noncancer patients is applicable (Geddes and Butler,
2002), while accepting that further research is required to establish
this. We defined the adequacy of dose of antidepressant drugs as
that specified in the British National Formulary (BNF)
(www.bnf.org). However, given recent evidence suggesting that
the tricyclic antidepressant drugs may be effective at a lower dose
of 75 mg (Furukawa et al, 2002), this was defined as the minimum
effective dose for these agents. Psychological treatment was
defined as a specified course of treatment with a recognised
professional of at least two treatment sessions. Referral to Mental
health services was defined to include referral to any discipline in
the local NHS services.
Analysis
First, the demographic characteristics of clinic attenders were
described and supplemented with more detailed medical informa-
tion on the 1 month subsample. Second, the numbers of patients
included at each stage of the screening process were recorded and
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losses at each stage of the process accounted for. Third, the
prevalence of MDD was calculated and an estimate was made that
took into account patient attrition during the screening process.
Finally, we described the characteristics and current treatment of
patients who were both diagnosed with MDD and potentially
eligible for management of their depression by an oncology
department-based service.
Ethical approval
The Local Research Ethics Committee approved the study.
RESULTS
Characteristics of the screened sample
We made a detailed case-note assessment, of 792 (14%) of the 5613
attenders screened. The majority (558 out of 792; 71%) were female
with a mean age of 60 years. Breast cancer was the largest group
(377 out of 792; 48%), with the remaining being approximately
equally divided between prostate, bladder, testes, and colorectal
and gynaecological cancers.
Number of cases of MDD identified
Figure 1 is a flow chart showing the number of patients on whom
data were recorded at each stage of the screening process. It
includes both those screened in the general oncology clinics by a
touch-screen computer, and those screened in the breast unit
clinics by paper questionnaire. There was a higher completion rate
of the HADS screening questionnaire in the oncology clinic (76%
compared with 64%), yielding an overall completion rate of 70%
(3938 out of 5613).
The data from these two outpatient departments were combined.
In the combined sample, 891 out of 3938 or 23% (95% confidence
intervals 21–24%) of completers scored above the cutoff of 15 or
more on the HADS. Although the majority of these high scorers
(570 out of 891; 64%) were assessed further by telephone interview,
a substantial number of patients (321) were lost to further
assessment at this stage. A number of patients (n¼ 79) were
ineligible for further assessment, almost all because of poor health
or poor prognosis. For a further 224 patients, interviews were not
achievable. The main reasons were failure to obtain permission
from the oncologist to contact the patient, administrative reasons
in 87 and refusal of permission in 27. Further losses were due to
failure to achieve contact with the patient (n¼ 96) and patient
discharge from the clinic (n¼ 14).
Stage one 
Stage two
Total HADS completed: 3938/5613 or
70% of all attenders 
Number of HADS completers with 
high scorers (≥15): 891/3938 or 23%
Number of high scorers interviewed: 
570/891 or 64%
Number diagnosed as having MDD: 
196/570 or 34% of those
interviewed
Not contacted for further 
assessment: 321 (no permission
from clinician 224; ineligible
79; refused 18) 
Total number of patients attending 
all clinics: 5613 
Number attending main cancer unit
September 99−September 2000: 
2832 
Number attending breast unit 
January 2000−September 2000: 
2781 
Completed HADS in main cancer 
unit: 2162/2832 or 76%
Completed HADS in breast unit:
1776/2781 or 64 %
Ineligible for study: 39 
20 chronic depression  
4 severe psychiatric illness. 
3 complicating medical 
problem
3 alcohol dependent 
3 too unwell 
2 cognitive impairment
4 unable to take part 
7 patients 
refused to 
answer
additional 
questions  
Sample on which we obtained a 
description of usual care 
management: 150 
Figure 1 Number of patients included at each stage of the screening process.
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A comparison of the sample of patients on whom telephone
interview was achieved with those on whom it was not (see Table 1)
showed small but statistically significant differences in age and
gender. The interviewed sample was slightly older and more likely
to be that of a female. The mean total HADs score of the two
groups was similar.
Major depressive disorder was diagnosed in 196 out of 570
(34%; 95% confidence interval 31–38%) of the high-scoring
patients on whom SCID interviews were achieved. This represents
196 out of 891 (22%) of all the high scorers on the HADS if those
not interviewed are included. In order to compensate for cases
missed because of failure to obtain an interview and given that the
mean HADs score of those interviewed was comparable to those
not interviewed, we have assumed that a similar percentage of the
high scorers not interviewed would have MDD. This is an
additional 109 cases (34% of 321). We can then estimate the total
number of cases of MDD in all high scorers, had we been able to
interview them, as 305. This gives an overall estimated prevalence
of MDD in those patients who completed the HADS screen of 305
out of 3938 (7.8%; 95% confidence intervals 6.9–8.6%). However,
this estimated prevalence in the population of oncology attenders
does not take into account those patients who refused to complete
the HADS at initial contact (1675 out of 5613; 30%). Therefore, the
‘true’ prevalence rate may be higher than found in this sample, as
there was an impression in the screening clinics that depressed
individuals were more likely to refuse invitations to participate in
the screening procedure.
Description of patients with MDD
Of the 196 patients identified as having MDD, seven refused to
provide further information. Of the remainder, 37 were considered
inappropriate for treatment by a cancer centre depression service:
20 patients had chronic MDD (depression with onset at least 1 year
prior to their first cancer diagnosis). Most of these patients had
received or were receiving specialist psychiatric treatment. A
further 19 patients were excluded for other reasons listed in
Figure 1. The final sample of cases of MDD considered suitable for
treatment in a cancer centre service and on whom assessments
were competed was therefore 150. The characteristics of these 150
patients are shown in Table 2.
The majority were females with breast cancer. Most had inactive
disease, with only a minority currently undergoing cytotoxic
treatment (other than taking anticancer medications such as
tamoxifen) at the time of screening. The median interval since
cancer diagnosis was 3 years, with a mode of 1 year. For a small
number of patients, 10 or more years had elapsed since their
original cancer diagnosis.
Nature of MDD
The median duration of the patient’s current depressive episode
was 6 months. For half of the sample, this was their first episode of
depression (see Table 3).
Treatment received
The treatment the patients with MDD reported having received for
their current episode of depression is shown in Figure 2. Overall,
only 23 out of 150 (15%) of the patients were judged to have
received or were currently receiving potentially effective evidence-
based treatment for MDD. Likely reasons for the failure to deliver
effective treatment were identified at every stage of their manage-
ment and are shown in Figure 2.
First, only half (74 out of 150; 49%) of the patients said that they
had even spoken with their GP or oncologist about feeling
depressed. Second, less than a third (43 out of 150; 29%) reported
being offered antidepressant drugs, and less than half of these were
taking an adequate dose (as defined in methods) at the time of
screening. Finally, only a small minority of patients (11 out of 150;
7%) had been referred to specialist mental health services
(psychology or psychiatry) and only (7 out of 150; 5%) had
received any formal psychological treatment for depression. These
findings indicate a potentially substantial unmet treatment need.
Table 1 Differences between those patients interviewed and those who
were not interviewed
Telephoned Not telephoned
Variable (N¼ 570) (N¼ 321) Statistic Significance
Mean (s.d.) age
in years
61.6 (11.8) 58.6 (14.1) t¼3.312 P¼ 0.001
Percentage
(number) female
89.1 (508) 70.1 (225) w2 48.159 Po0.001
Mean (s.d.) total
HAD score
19.2 (4.7) 19.6 (4.5) t¼ 1.57 P¼ 0.117
Table 2 Demographic and medical characteristics of 150 patients with
comorbid MDD.
Demographic characteristics
Mean (s.d.) age in years: 57 (10.8) (range 31–83)
Female 135 (90)
Cancer site
Breast 116 (77)
Bladder 4 (3)
Prostate 8 (5)
Testicular 3 (2)
Colorectal 7 (5)
Thyroid 1 (1)
Gynaecology 11 (7)
Disease state
No active disease 117 (78)
Local disease present 17 (11)
Metastases 16 (11)
Stage of treatmenta
Active treatment 47 (31)
Monitoring only 103 (67)
Median (range) duration since first
diagnosis in years
3 (0 to 29)
aStage of treatment was operationalised as follows: on active treatment ¼ patient
undergoing chemotherapy or radiotherapy, under investigation or about to have
surgery; monitoring ¼ patient with no active disease but attending hospital for
regular check-ups, monthly to annually in frequency (may be taking hormone
treatment such as Tamoxifen). Number (percentage) with each characteristic unless
otherwise specified.
Table 3 Depression characteristics of the study sample of 150 patients
with comorbid MDD
Median duration (range) of depressive episode (months) 6 (1–216)
Timing of onset relative to cancer diagnosis
With initial diagnosis 36 (24)
After diagnosis 97 (65)
With recurrence 17 (11)
Previous depression
No previous episodes 77 (51)
One previous episode 49 (33)
Two or more previous episodes 24 (16)
Number (percentage) with each characteristic unless otherwise specified.
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DISCUSSION
This study shows that it is possible routinely to identify cases of MDD
in large numbers of oncology outpatients using a two-stage screening
procedure. The proportion of attenders found to meet the criteria for
MDD was lower than initially expected at approximately 8%. The
most notable finding was that of the patients found both to have MDD
and to be potentially suitable for treatment in a cancer centre-based
depression service, the vast majority (85%) were not receiving any
appropriate evidence-based treatment for depression.
Screening programme
This particular screening programme aimed to identify patients who
met diagnostic criteria for MDD as opposed to those with only more
general distress. The HADs has been previously reported as being
useful for this purpose (Bjelland et al, 2002), although others have
reported it to be insensitive (Ramirez et al, 1995; Hall et al, 1999). A
check of sensitivity in the population studied found it to be adequate
at the cutoff used but that it required that three patients be
interviewed for every case of MDD detected. The touch-screen
administration system has also been previously found to be both
generally acceptable to patients (Velikova et al, 1999) and to achieve a
better completion rate than pencil and paper administration. The use
of diagnostic interviewing over the telephone for high scorers on the
HADS was also able to identify cases of MDD and was also, and
perhaps surprisingly, very acceptable to patients (Allen et al, 2003).
The overall performance of the screening procedure was,
however, impaired by ‘real-world’ practical and organisational
difficulties. The main ones were: (1) an administrative failure to
obtain HADs scores on all outpatient attendees, especially in the
subsample who used pencil and paper questionnaires; (2) failure to
achieve telephone interviews on all of those who scored highly on
the HAD scale. Although these problems were at least partly
remediable by changes in the screening protocol, they serve to
remind us that the practical screening of large numbers of patients
with limited resources is inevitably an imperfect process. The
system was also opportunistic, screening patients only when they
attended the oncology clinic. These times are not necessarily
optimal for screening for depression. The effort invested in the
screening to the number of cases identified was also relatively high,
although the cost effectiveness of the process might be enhanced
by using it to also identify patients with other problems such as
anxiety, fatigue, and poor quality of life.
Number of cases of depression identified
The observation that only 8 percent of the sample had MDD, even
after correction for the omitted telephone interviews, was
surprising. For example, a recent systematic review found a
median prevalence of 15% among patients with advanced cancer
(Hotopf et al, 2002). The relatively low prevalence in this study was
probably because our sample was composed mainly of outpatients
with inactive cancer, many of whom (particularly those in the
breast service) were attending only for long-term follow-up, that is,
most were not patients with advanced cancer and a few were
undergoing active treatment for cancer. The sample characteristics
reflected our choice of clinics and exclusion of patients with very
limited life expectancy. It is, however, arguable that the group of
patients we identified are precisely those suitable for treatment by
an oncology service-based depression programme (Sharpe et al,
2003, companion paper). A different sample with a higher
proportion of sick patients receiving active treatment would have
been likely to have a higher prevalence of depression. Although
our audit of the screening process suggested that the self-rated
questionnaire missed few interview positive cases of MDD, there
was a strong impression that some patients, especially men, either
avoided the screening procedure or denied symptoms of depres-
sion that were in fact present. This phenomenon may also lead to
underestimation of the true prevalence of MDD.
Unmet treatment need
Importantly, only a minority of the cases of MDD identified
appeared to have been explicitly recognised and only a small
minority (15%) had received evidence-based therapy. A high level of
unmet need for depression treatment has been recently reported
(Fallowfield et al, 2001). Of more concern is the observation that
similar findings were reported 20 years ago (Maguire et al, 1980).
While it is possible that our estimate of unmet treatment needs was
artificially increased because patients who had received effective
treatment no longer meet the criteria for MDD, this finding has
substantial implications for outpatient cancer services. Furthermore,
the failings identified were at every stage of management; and
150 patients identified as having
MDD on screening  
Only  24/40  patients were 
prescribed a therapeutic
dose of antidepressants of
which 16 patients actually
took the therapeutic dose 
prescribed
Only 63/150 or 42 % of the 
sample received any treatment. 
Only 74/150 patients or 49 % of the
sample reported speaking 
with their doctors about depression
11/150 or 7 % referred
to mental health services: 
4 saw a psychologist 
3 saw a psychiatrist  
4 did not attend for their 
appointment
Only 40/150 or 27 %  
were offered an 
antidepressant by their GP
(of which 33/40 took it)
In total, only 23 /150 or 15 % of the sample were judged to 
have received a potentially effective evidence-based treatment 
for MDD. In total, only19/150 or 13 % were taking a 
therapeutic dose of an antidepressant drug and only 7/150 had 
received formal psychological treatment. In other words, 127/150 
or 85 % of patients had not had their need for treatment of
MDD met
All 7 patients who were 
referred to (and attended) a 
mental service received 
psychotherapy. Three cases 
also received a therapeutic 
dose of an antidepressant
Figure 2 Flow chart documenting self-report of management of
depression.
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include recognition, prescribing, patient adherence to medication,
and availability of psychotherapy. They may also indicate patients’
own views and preferences about the need for a desirability of
treatment for depression.
Recognition of depression In our experience, the failure to
recognise depression occurs in part because both doctor and patient
are focused on the medical management of the patient’s cancer. Even
when detected, the depression may be disregarded as ‘understandable’
in someone with cancer. The implication is that questions about
depression should be routinely asked and the responses acted on.
Prescribing of and adherence to antidepressant drugs In patients
in whom MDD had been recognised, two-thirds reported being
offered an antidepressant drug, but only a small minority were
actually prescribed a therapeutic dose. This is because a substantial
proportion of these patients had decided not to take the drug and of
those who had taken it, a further proportion had not achieved a
therapeutic dose, probably because the patients’ general practitioner
(George et al, 2000) did not increase doses. Even if a therapeutic dose
was prescribed, a number either did not take it or had stopped taking
it after only a short period. This poor adherence to antidepressant
drug therapy has been previously noted (Lin et al, 1995). The
implication is that prescribing is not enough – explanation and
monitoring are also required.
Referral to specialist mental health services and receipt of
psychotherapies Very few patients reported having being referred
to specialist mental health services and only five patients reported
receiving an evidence-based psychotherapy such as cognitive
behaviour therapy or interpersonal therapy (Geddes and Butler,
2002). These low rates probably reflect a combination of limited
availability of local services, especially for patients seen as
medically ill and stigma (Wessely, 1996). The implication is that
integrated accessible, non-stigmatising, services are required.
Patients In addition to failings in medical management, we also
have to consider the extent to which cancer patients actually want
to have their depression recognised and treated. In our experience,
not all do. This issue is addressed further in a companion paper
(Sharpe et al, 2003).
Limitations
The main limitation of this study is that the sample reported on is not
representative of all oncology outpatient attenders. This is because:
(a) for practical reasons, only a selected number of clinics were
screened, (b) as screening was designed to detect cases of MDD
suitable for treatment in an Oncology Department Depression Service,
patients with very limited life expectancy and patients with very
chronic depression were excluded. It can, however, be argued that it is
representative of those patients who are suitable for treatment by an
oncology service-based depression treatment programme.
Despite our best efforts, there were a number of practical
difficulties in the screening procedure and a large number of
potential cases of major depression were lost during the process.
Finally, while we have assumed that MDD in cancer patients would
respond to treatments used for MDD in patients who do not have
cancer, we acknowledge that the evidence supporting this
assumption is limited and that further research into the effective
treatment of depression in patients with medical conditions and
comorbid depression is urgently required.
Implications
These findings have implications for both practice and for further
research. In clinical practice, the findings highlight the high rate of
untreated depression in medical populations in general and cancer
populations in particular. They also demonstrate the potential value
of screening. There are, however, important caveats. First, there is,
little point in screening unless it is associated with an intervention
programme (Gilbody et al, 2001). We report on such a programme
in a companion paper (Sharpe et al, 2003). Second, screening places
a burden on both patients and staff. Further developments need to
explore ways of making it more efficient and cost-effective. For
example, it could be used to screen simultaneously for depression,
anxiety, fatigue, and other symptoms as well as providing serial
measures of quality of life for monitoring progress.
Conclusions
It is possible to identify cases of MDD in patients attending a large
and busy oncology outpatient department with only limited
resources, especially if automated screening and telephone inter-
views are used. However, even with such a system, potential cases
of major depression are likely to be missed. We suggest that such a
system could be more cost effective if used to screen for a range of
problems and not simply major depression.
The prevalence of major depression identified in ambulatory
outpatients (most of whom were attending for follow-up rather
than active treatment), with poor prognosis patients excluded, was
surprisingly low. However, only a minority of patients who could
potentially be treated for depression within the cancer service had
actually received effective treatment. The failure to recognise and
treat MDD in cancer patients deserves further attention. Specifi-
cally, we would argue that there is a need for the identification and
treatment of depression to be better integrated with the patient’s
oncological care and to be carried out in collaboration with their
general practitioner. We have piloted such a service and the results
of this are reported elsewhere (Sharpe et al, 2003).
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